Best practices on immunomodulators and biologic agents for ulcerative colitis and Crohn's disease in Asia
| Autor: | Marcellus Simadibrata, Ida Hilmi, Siew C. Ng, Wee Chian Lim, Khean-Lee Goh, Richard Geary, Nazri Mustaffa, Colitis, Pises Pisespongsa, Wai K. Leung, Min Hu Chen, Sai Wei Chuah, Byong Duk Ye, Rupa Banerjee, Jose D. Sollano, Evan G. Ong, Rupert W. Leong, Rungsun Rerknimitr, Vineet Ahuja, Tadakazu Hisamatsu, David E. Ong, Murdani Abdullah, Khoon Lin Ling, Deng-Chyang Wu, Qin Ouyang, Zhi Hua Ran, Govind K. Makharia, Shu-Chen Wei, Julajak Limsrivilai, Choon Jin Ooi, Dong Il Park, Raja Affendi Raja Ali, Janaka de Silva, Suk-Kyun Yang |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Crohn's disease
medicine.medical_specialty Hepatology business.industry Gastroenterology Biosimilar Disease medicine.disease Inflammatory bowel disease Ulcerative colitis digestive system diseases Infliximab 03 medical and health sciences 0302 clinical medicine 030220 oncology & carcinogenesis Adalimumab medicine 030211 gastroenterology & hepatology Colitis Intensive care medicine business medicine.drug |
| Zdroj: | Journal of Gastroenterology and Hepatology. 34:1296-1315 |
| ISSN: | 0815-9319 |
| DOI: | 10.1111/jgh.14648 |
| Popis: | The Asia-Pacific Working Group on Inflammatory Bowel Disease was established in Cebu, Philippines, under the auspices of the Asia-Pacific Association of Gastroenterology with the goal of improving inflammatory bowel disease care in Asia. This consensus is carried out in collaboration with Asian Organization for Crohn's and Colitis. With biologic agents and biosimilars becoming more established, it is necessary to conduct a review on existing literature and establish a consensus on when and how to introduce biologic agents and biosimilars in conjunction with conventional treatments for ulcerative colitis and Crohn's disease in Asia. These statements also address how pharmacogenetics influences the treatments of ulcerative colitis and Crohn's disease and provides guidance on response monitoring and strategies to restore loss of response. Finally, the review includes statements on how to manage treatment alongside possible hepatitis B and tuberculosis infections, both common in Asia. These statements have been prepared and voted upon by members of inflammatory bowel disease workgroup employing the modified Delphi process. These statements do not intend to be all-encompassing, and future revisions are likely as new data continue to emerge. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text